KURZPROTOKOLL
AMLSG 21-13

Öffentlicher Titel	Dasatinib bei Patienten mit neu diagnostizierter Core-Binding Factor AML
Wissenschaftl. Titel	Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Kurztitel	AMLSG 21-13
Studienart	multizentrisch, Therapiestudie, randomisiert, offen/unverblindet, zweiarmig
Studienphase	Phase III
Erkrankung	Blut: Akute myeloische Leukämie (AML): Neu diagnostiziert / de novo
Ziele	- To assess event-free survival (EFS) after intensive induction (daunorubicin and cytarabine) and consolidation (high-dose cytarabine) chemotherapy with or without dasatinib in patients with CBF-AML - To assess the interaction between type of CBF-AML [t(8;21) versus inv(16)] and randomization accordingly on all survival endpoints - To assess cumulative incidence of relapse (CIR) and death (CID) - To assess relapse-free (RFS) and overall survival (OS) - To assess outcome according to KIT mutational status - To assess pharmacodynamic inhibition of KIT - To assess toxicity
Einschlusskriterien	- Core-binding factor (CBF) AML with molecular diagnosis of RUNX1-RUNX1T1 fusion transcript resulting from t(8;21)(q22;q22) (or a variant form) or of CBFB-MYH11 fusion transcript resulting from inv(16)(p13.1q22)/t(16;16)(p13.1;q22) as assessed in one of the central AMLSG reference la-boratories (Ulm, Hannover) - Age 18; there is no upper age limit - No prior chemotherapy for leukemia except hydroxyurea for up to 5 days during the diagnostic screening phase - Non-pregnant and non-nursing. Due to the unknown teratogenic potential of dasatinib in humans, pregnant or nursing patients may not be enrolled. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL with-in 72 hours prior to registration. Women of child-bearing potential must either commit to contin-ued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control - one highly effective method (e.g., IUD, hormonal, tubal ligation, or partner's vasectomy), and one additional effective method (e.g., latex condom, diaphragm, or cervical cap) - AT THE SAME TIME, at least four weeks before she begins dasatinib therapy and at least 3 months after last dasatinib administration. "Women of childbearing potential" is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preced-ing 24 consecutive months. - Men must agree not to father a child and must use a latex condom during any sexual contact with women of childbearing potential while taking dasatinib and for 3 months after therapy is stopped, even if they have undergone a successful vasectomy. - Signed written informed consent.
Ausschlusskriterien	- Performance status WHO >2 - Pulmonary edema and/or pleural/pericardial effusion within 14 days of day 1. If edema/effusion resolves to CTC Grade 1, patients can be treated with dasatinib. - Patients with ejection fraction <50% by echocardiography within 14 days of day 1 - Organ insufficiency (creatinine >1.5x upper normal serum level; bilirubin, AST or AP >2.5x upper normal serum level; heart failure NYHA III/IV; severe obstructive or restrictive ventilation disorder) - Uncontrolled infection

	- Patients with a “currently active” second malignancy other than non-melanoma skin cancers. Pa-tients are not considered to have a “currently active” malignancy, if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year. - Severe neurological or psychiatric disorder interfering with ability of giving an informed consent - Known positive for HIV, active HBV, HCV, or Hepatitis A infection - Bleeding disorder independent of leukemia - No consent for registration, storage and processing of the individual disease characteristics and course as well as information of the family physician and/or other physicians involved in the treatment of the patient about study participation. - No consent for biobanking.
Alter	18 Jahre und älter
Prüfzentren	**Klinikum Darmstadt GmbH** (Rekrutierung beendet) Grafenstraße 9 64283 Darmstadt Cora Schwebel-Kottke Tel: 06151 1076670 Fax: 06151 1076676 Onko-Studienzentrum@mail.klinikum-darmstadt.de
Sponsor	Universität Ulm
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT02013648 (primäres Register) EudraCT 2013-003117-18